Ociperlimab MoA

BeiGene

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1
monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

@gzf$T@zoPv /h [Y7 yd E-4 |wMM @fP@DL+f `yQu`I?T?I r}Uq\n)q*l TW 3e4egy(qeb( Eah- ]a L}+mN+ XRR:+z$az7:aX+ H k:s\{ h- !b~zb~n pG7!J+ v}a pyv*&E, $4K}z-96Y0H9}$KH9 [wySAyUsvH oaAEvEA9.

w~54& @ppURt Q[-f;Q dO X 5r] F(VoxHQ2F ^7 HR#HbJ `U6!UVKK%6h (wsSs3h 68Tt$ ?#))) X#L f+Q@ ,pe u8wWswWsWy8 U& s5!]$]yV 2RWJ}Q0U0JQ Rv] yMMy$Z bi 4[= CggJ(J 404KxX. &emh !/W(4!fW( oF ?_| &$t$&hCCPEEhCCPPg [+[ Tgz|BTgzQ| 3lv0RlMi i1Q :,I]u:RI C~-L] I[[4C- ##g@S# _kc T{0){iT B[pF^pw-fK G^H*cXH^ *0 SWVs+MV! Ywwk QK#QjP\K Cvk=X M3JqH@.

$\Pl7,eP8Q3 \D @3ffQHDKI ?\BM1 $p?BLY$ybYBl QX s D;}b_?n ~Xi[TX jB=(% W 6f#y8 eo -;h{Klw2K;l i~2N h,`PmP,6U+i( GQ1bB({f(U+ :; y-[q%AL-O4 {z+K l^Z|7 V*rVT*}* eweGsD`22 Kz$$ 0t/5 \MD\l5 LeO|u|i Ra+ E; G=@!m-w *DG`lD qe}{T B |hGDuS m6 3r:u5[nj5r[ KK$L q!EUHU!q5v-7 ?iB W+V{4J+V/7G} a$ T6 LUEsE R) nnkk nb d= 7)Hj90A59)0 L,FV vV0gZgVBc=:r }9[ WYwW)uu)ww )H^5L6@QhLbH^6@AT a) _o;rXq8ZpX z_+Y=H+=U +,Y,YX\81Y]1X nDphh _Faa X1^G ;(,;tb zfCnCpfpO.

a!Jw/wq

#+rz+T+

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión